A new global study sponsored by the National Institute of Allergy and Infectious Diseases has determined that cabotegravir, an antiretroviral medication used for HIV treatment, is safe for use before and during pregnancy. The study analyzed the pregnancy and infant outcomes of using long-acting injectable cabotegravir in more than 300 pregnant women. These findings fill an important knowledge gap that will help increase access to HIV treatment for cisgender women before, during, and after pregnancy. 

Identifying gaps and priorities at the intersection of HIV and women's health is a goal for the HIV and Women Signature Program, which was established in February 2023 by NIH’s Office of AIDS Research and ORWH. The program has convened an HIV and Women Working Group to establish an intersectional, equity-informed, data-driven approach to research on HIV and women.